$46.51
0.21% day before yesterday
Nasdaq, Dec 24, 09:41 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$46.51
+4.26 10.08% 1M
+0.79 1.73% 6M
+13.21 39.67% YTD
+12.69 37.52% 1Y
+30.68 193.81% 3Y
+25.80 124.58% 5Y
+41.22 779.21% 10Y
+36.69 373.63% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.10 0.21%

New AI Insights on Exelixis, Inc. Insights AI Insights on Exelixis, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$12.5b
Enterprise Value
$11.5b
Net debt
positive
Cash
$988.5m
Shares outstanding
268.1m
Valuation (TTM | estimate)
P/E
19.1 | 14.7
P/S
5.4 | 4.7
EV/Sales
5.0 | 4.3
EV/FCF
14.7
P/B
5.8
Financial Health
Equity Ratio
76.1%
Return on Equity
23.2%
ROCE
33.5%
ROIC
38.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.3b | $2.7b
EBITDA
$850.0m | $1.0b
EBIT
$820.3m | $987.5m
Net Income
$677.9m | $847.1m
Free Cash Flow
$779.8m
Growth (TTM | estimate)
Revenue
9.9% | 23.0%
EBITDA
33.7% | 39.7%
EBIT
34.8% | 43.1%
Net Income
45.2% | 62.5%
Free Cash Flow
80.3%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
37.2% | 37.7%
EBIT
35.9%
Net
29.6% | 31.8%
Free Cash Flow
34.1%
More
EPS
$2.4
FCF per Share
$2.9
Short interest
11.0%
Employees
1k
Rev per Employee
$1.9m
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Exelixis, Inc. forecast:

16x Buy
59%
11x Hold
41%

Analyst Opinions

27 Analysts have issued a Exelixis, Inc. forecast:

Buy
59%
Hold
41%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '25
+/-
%
2,288 2,288
10% 10%
100%
- Direct Costs 77 77
1% 1%
3%
2,211 2,211
10% 10%
97%
- Selling and Administrative Expenses 530 530
8% 8%
23%
- Research and Development Expense 861 861
5% 5%
38%
850 850
34% 34%
37%
- Depreciation and Amortization 30 30
7% 7%
1%
EBIT (Operating Income) EBIT 820 820
35% 35%
36%
Net Profit 678 678
45% 45%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Neutral
Seeking Alpha
15 days ago
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
Neutral
Business Wire
22 days ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis' R&D activities and outline the company's strategy to advance future ...
Positive
The Motley Fool
24 days ago
Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today